Muvalaplin
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Muvalaplin
- Molecular weight
- 710.92
- Structure (SMILES)
- O=C(O)[C@@H](Cc1cccc(CN(Cc2cccc(C[C@H](C(=O)O)[C@H]3CCNC3)c2)Cc2cccc(C[C@H](C(=O)O)[C@H]3CCNC3)c2)c1)[C@H]1CCNC1
- (1<sup>3</sup>R,2S,10S,11<sup>3</sup>R)-6-[(3-{(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl}phenyl)methyl]-6-aza-1,11(3)-dipyrrolidina-4,8(1,3)-dibenzenaundecaphane-2,10-dicarboxylic acid
- 1 sup 3 sup r 2s 10s 11 sup 3 sup r 6 3 2s 2 carboxy 2 3r pyrrolidin 3 yl ethyl phenyl methyl 6 aza 1 11 3 dipyrrolidina 4 8 1 3 dibenzenaundecaphane 2 10 dicarboxylic acid
- ly 3473329
- LY-3473329
- ly3473329
- Ly3473329
- LY3473329
- muvalaplin
- Muvalaplin
- muvalaplin [INN]
- MUVALAPLIN [USAN]
- Muvalaplin [WHO-DD]
- muvalaplin inn
- muvalaplin usan
- muvalaplin who dd
- muvalaplina
- Muvalaplina
- muvalapline
- Muvalapline
- CAS registry numbers
- 2565656-70-2
- ChEMBL ID
- CHEMBL4802585
- InChIKey
- BRLGERLDHZRETI-BGBFCPIGSA-N
- PubChem compound IDs
- 155369486
- FDA ingredient codes (UNII)
- HSU2KY4EFK
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- muvalaplin
- Type
- Synthetic organic
- Drug name stem
- -aplin; -laplin
- Condition
- Coronary Artery Disease
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001645
- Subject identifier
- D003324
- Condition
- Renal Insufficiency
- Highest recorded phase
- 1
- Condition identifier
- HP:0000083
- Subject identifier
- D051437
- Condition identifier
- EFO_0000319
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001645
- Condition identifier
- HP_0000083
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004995
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005010
Trial references
- NCT05778864
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 6
- Polar surface area
- 151.23
- Calculated partition coefficient (ALogP)
- 4.45
- Calculated partition coefficient (XLogP)
- -2.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 18
- Heavy atoms
- 52
- Molecular formula
- C42H54N4O6
- Monoisotopic mass
- 710.40433546
- Natural product
- No
Related records
Trials (6)
- A Study of Carbon-14-Labelled [14C] LY3473329 in Healthy Male Participants
- A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
- A Study of LY3473329 in Healthy Japanese Participants
- A Study of LY3473329 in Healthy Participants
- A Study of LY3473329 in Participants With Impaired and Normal Renal Function
- Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
In development for (3)
- Cardiovascular disorder Phase 2
- Coronary artery disorder Phase 1
- Kidney failure Phase 1